Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Erlotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 15/20 | 0.94 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.94 |
| ▸ | GAK | O14976 | 4/20 | 0.94 |
| ▸ | KDR | P35968 | 3/20 | 0.94 |
| ▸ | ILK | Q13418 | 2/20 | 0.94 |
| ▸ | FLT1 | P17948 | 2/20 | 0.94 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.94 |
| ▸ | BUB1 | O43683 | 2/20 | 0.94 |
| ▸ | STK10 | O94804 | 2/20 | 0.94 |
| ▸ | ABL1 | P00519 | 2/20 | 0.94 |
| ▸ | LCK | P06239 | 2/20 | 0.94 |
| ▸ | LYN | P07948 | 2/20 | 0.94 |
| ▸ | RET | P07949 | 2/20 | 0.94 |
| ▸ | SRC | P12931 | 2/20 | 0.94 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.94 |
| ▸ | FECH | P22830 | 2/20 | 0.94 |
| ▸ | FLT3 | P36888 | 2/20 | 0.94 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.94 |
| ▸ | PLK4 | O00444 | 1/20 | 0.94 |
| ▸ | CIT | O14578 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erlotinib SCHEMBL29120903 | 0.97 | EGFR (0.96) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL30362833 | 0.97 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL29351329 | 0.97 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL3667407 | 0.97 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL8413 | 0.97 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL1959332 | 0.96 | EGFR (0.98) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL18563 | 0.96 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL21176918 | 0.96 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL16767632 | 0.96 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL417841 | 0.96 | EGFR (0.98) | EGFRERBB2GAKKDRILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111904508-A | Surgical suturing device | 柯惠LP公司 | 2020-11-10 | — | — | CN | claimed |
| CN-111904509-A | Surgical suturing device | 柯惠LP公司 | 2020-11-10 | — | — | CN | claimed |
| CN-111904507-A | Surgical suturing device | 柯惠LP公司 | 2020-11-10 | — | — | CN | claimed |
| CN-115803092-A | SIRP alpha deficient macrophages for the treatment of cancer | 乔治亚州立大学研究基金公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-112770779-B | Cellulose composition, tablet and orally disintegrating tablet | 旭化成株式会社 | 2022-07-22 | — | — | CN | disclosed |
| CN-114514035-A | Compositions and methods for delivering therapeutic biologies for treatment of diseases | 伊勒卓菲公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-114466658-A | Orally delivered therapeutic compositions and uses thereof | 沈海发 | 2022-05-10 | — | — | CN | disclosed |
| CN-114340636-A | Method of treatment | 细胞内治疗公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-113366023-A | Compositions and methods for stimulating natural killer cells | 弗罗里达中央大学研究基金会 | 2021-09-07 | — | — | CN | disclosed |